In this study, we identify a mechanistic link, allantoin, the oxidative byproduct of UA often dismissed as biologically inert, drives MASLD progression by disrupting lipid and cholesterol homeostasis via PPARα regulation. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.